Grenye O'Malley1, Laurel H Messer2, Carol J Levy1, Jordan E Pinsker3, Gregory P Forlenza2, Elvira Isganaitis4, Yogish C Kudva5, Laya Ekhlaspour6, Dan Raghinaru7, John Lum7, Sue A Brown8. 1. Division of Endocrinology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA. 2. Barbara Davis Center for Diabetes, University of Colorado, Aurora, Colorado, USA. 3. Sansum Diabetes Research Institute, Santa Barbara, California, USA. 4. Research Division, Joslin Diabetes Center and Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA. 5. Division of Endocrinology, Diabetes, Metabolism and Nutrition, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA. 6. Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA. 7. Jaeb Center for Health Research, Tampa, Florida, USA. 8. Division of Endocrinology, Department of Medicine, Center for Diabetes Technology, University of Virginia, Charlottesville, Virginia, USA.
Abstract
Background: Data are limited on the need for and benefits of pump setting optimization with automated insulin delivery. We examined clinical management of a closed-loop control (CLC) system and its relationship to glycemic outcomes. Materials and Methods: We analyzed personal parameter adjustments in 168 participants in a 6-month multicenter trial of CLC with Control-IQ versus sensor-augmented pump (SAP) therapy. Preset parameters (BR = basal rates, CF = correction factors, CR = carbohydrate ratios) were optimized at randomization, 2 and 13 weeks, for safety issues, participant concerns, or initiation by participants' usual diabetes care team. Time in range (TIR 70-180 mg/dL) was compared in the week before and after parameter changes. Results: In 607 encounters for parameter changes, there were fewer adjustments for CLC than SAP (3.4 vs. 4.1/participant). Adjustments involved BR (CLC 69%, SAP 80%), CR (CLC 68%, SAP 50%), CF (CLC 44%, SAP 41%), and overnight parameters (CLC 62%, SAP 75%). TIR before and after adjustments was 71.2% and 71.3% for CLC and 61.0% and 62.9% for SAP. The highest baseline HbA1c CLC subgroup had the largest TIR improvement (51.2% vs. 57.7%). When a CR was made more aggressive in the CLC group, postprandial time >180 mg/dL was 43.1% before the change and 36.0% after the change. The median postprandial time <70 mg/dL before making CR less aggressive was 1.8%, and after the change was 0.7%. Conclusions: No difference in TIR was detected with parameter changes overall, but they may have an effect in higher HbA1c subgroups or following user-directed boluses, suggesting that changes may matter more in suboptimal control or during discrete periods of the day. Clinical Trials Registration number: NCT03563313.
Background: Data are limited on the need for and benefits of pump setting optimization with automated insulin delivery. We examined clinical management of a closed-loop control (CLC) system and its relationship to glycemic outcomes. Materials and Methods: We analyzed personal parameter adjustments in 168 participants in a 6-month multicenter trial of CLC with Control-IQ versus sensor-augmented pump (SAP) therapy. Preset parameters (BR = basal rates, CF = correction factors, CR = carbohydrate ratios) were optimized at randomization, 2 and 13 weeks, for safety issues, participant concerns, or initiation by participants' usual diabetes care team. Time in range (TIR 70-180 mg/dL) was compared in the week before and after parameter changes. Results: In 607 encounters for parameter changes, there were fewer adjustments for CLC than SAP (3.4 vs. 4.1/participant). Adjustments involved BR (CLC 69%, SAP 80%), CR (CLC 68%, SAP 50%), CF (CLC 44%, SAP 41%), and overnight parameters (CLC 62%, SAP 75%). TIR before and after adjustments was 71.2% and 71.3% for CLC and 61.0% and 62.9% for SAP. The highest baseline HbA1c CLC subgroup had the largest TIR improvement (51.2% vs. 57.7%). When a CR was made more aggressive in the CLC group, postprandial time >180 mg/dL was 43.1% before the change and 36.0% after the change. The median postprandial time <70 mg/dL before making CR less aggressive was 1.8%, and after the change was 0.7%. Conclusions: No difference in TIR was detected with parameter changes overall, but they may have an effect in higher HbA1c subgroups or following user-directed boluses, suggesting that changes may matter more in suboptimal control or during discrete periods of the day. Clinical Trials Registration number: NCT03563313.
Authors: Sue A Brown; Boris P Kovatchev; Dan Raghinaru; John W Lum; Bruce A Buckingham; Yogish C Kudva; Lori M Laffel; Carol J Levy; Jordan E Pinsker; R Paul Wadwa; Eyal Dassau; Francis J Doyle; Stacey M Anderson; Mei Mei Church; Vikash Dadlani; Laya Ekhlaspour; Gregory P Forlenza; Elvira Isganaitis; David W Lam; Craig Kollman; Roy W Beck Journal: N Engl J Med Date: 2019-10-16 Impact factor: 91.245
Authors: Daniel R Cherñavvsky; Mark D DeBoer; Patrick Keith-Hynes; Benton Mize; Molly McElwee; Susan Demartini; Spencer F Dunsmore; Christian Wakeman; Boris P Kovatchev; Marc D Breton Journal: Pediatr Diabetes Date: 2014-10-27 Impact factor: 4.866
Authors: Laurel H Messer; Gregory P Forlenza; Jennifer L Sherr; R Paul Wadwa; Bruce A Buckingham; Stuart A Weinzimer; David M Maahs; Robert H Slover Journal: Diabetes Care Date: 2018-02-14 Impact factor: 19.112
Authors: Melissa J Schoelwer; Jessica L Robic; Thibault Gautier; Chiara Fabris; Kelly Carr; Mary Clancy-Oliveri; Sue A Brown; Stacey M Anderson; Mark D DeBoer; Daniel R Cherñavvsky; Marc D Breton Journal: Diabetes Technol Ther Date: 2020-03-02 Impact factor: 6.118
Authors: Michael P Stone; Pratik Agrawal; Xiaoxiao Chen; Margaret Liu; John Shin; Toni L Cordero; Francine R Kaufman Journal: Diabetes Technol Ther Date: 2018-08-30 Impact factor: 6.118
Authors: Satish K Garg; Stuart A Weinzimer; William V Tamborlane; Bruce A Buckingham; Bruce W Bode; Timothy S Bailey; Ronald L Brazg; Jacob Ilany; Robert H Slover; Stacey M Anderson; Richard M Bergenstal; Benyamin Grosman; Anirban Roy; Toni L Cordero; John Shin; Scott W Lee; Francine R Kaufman Journal: Diabetes Technol Ther Date: 2017-01-30 Impact factor: 6.118
Authors: Rayhan A Lal; Marina Basina; David M Maahs; Korey Hood; Bruce Buckingham; Darrell M Wilson Journal: Diabetes Care Date: 2019-09-23 Impact factor: 19.112
Authors: Stuart A Weinzimer; Ryan J Bailey; Richard M Bergenstal; Revital Nimri; Roy W Beck; Desmond Schatz; Louise Ambler-Osborn; Darja Smigoc Schweiger; Thekla von dem Berge; Judy Sibayan; Mary L Johnson; Peter Calhoun; Moshe Phillip Journal: Diabetes Technol Ther Date: 2022-04-28 Impact factor: 7.337